Literature DB >> 20099135

Adjuvant activity of cytokines.

Michael G Tovey1, Christophe Lallemand.   

Abstract

The activity of several potent adjuvants, including incomplete Freund's adjuvant, CpG oligodeoxynucleotides, and alum, has been shown to be due at least in part to the induction of cytokines, including type I interferons (IFNs), IFN-gamma, interleukin-2 (IL-2), and IL-12, that play key roles in the regulation of innate and adaptive immunity. The relatively short half-life of recombinant homologues of cytokines has limited their use as vaccine adjuvants. These difficulties have been overcome by encapsulation into liposomes and the use of cytokine expression vectors co-administered with DNA vaccines. Although a number of cytokines including IFN-alpha, IFN-gamma, IL-2, IL-12, IL-15, IL-18, IL-21, GM-CSF, and Flt-3 ligand have been shown to potentiate the immune response to vaccination in various experimental models, the full potential of cytokines as vaccine adjuvants remains to be established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20099135     DOI: 10.1007/978-1-60761-585-9_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  Regulation of innate CD8+ T-cell activation mediated by cytokines.

Authors:  Bailey E Freeman; Erika Hammarlund; Hans-Peter Raué; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 2.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

3.  Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

Authors:  James K Coleman; Ruiyu Pu; Marcus M Martin; Ezra N Noon-Song; Raphael Zwijnenberg; Janet K Yamamoto
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

Review 4.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

Review 5.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

6.  A eukaryotic expression plasmid carrying chicken interleukin-18 enhances the response to newcastle disease virus vaccine.

Authors:  Chen Wang; Xiaokang Li; Chunjie Zhang; Tingcai Wu; Yinju Li; Xiangchao Cheng
Journal:  Clin Vaccine Immunol       Date:  2014-10-29

Review 7.  Biomimetic delivery with micro- and nanoparticles.

Authors:  Stephen C Balmert; Steven R Little
Journal:  Adv Mater       Date:  2012-04-23       Impact factor: 30.849

Review 8.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

9.  Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune response.

Authors:  Kate M Edwards; Meredith A Pung; Lianne M Tomfohr; Michael G Ziegler; John P Campbell; Mark T Drayson; Paul J Mills
Journal:  Vaccine       Date:  2012-08-22       Impact factor: 3.641

10.  A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.

Authors:  L Martínez-Gil; P H Goff; R Hai; A García-Sastre; M L Shaw; P Palese
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.